Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor - an update on neuroendocrine neoplasm's treatment : A case report
Mirallas, Oriol (Vall d'Hebron Institut d'Oncologia)
Saoudi, Nadia (Vall d'Hebron Institut d'Oncologia)
Gomez-Puerto, Diego (Vall d'Hebron Institut d'Oncologia)
Riveiro Barciela, Mar (Hospital Universitari Vall d'Hebron)
Merino, Xavier (Hospital Universitari Vall d'Hebron)
Auger, Cristina (Hospital Universitari Vall d'Hebron)
Landolfi, Stefania (Hospital Universitari Vall d'Hebron)
Blanco, Laia (Hospital Universitari Vall d'Hebron)
Garcia-Burillo, Amparo (Hospital Universitari Vall d'Hebron)
Molero, Xavier (Hospital Universitari Vall d'Hebron)
Salcedo, Maria-Teresa (Hospital Universitari Vall d'Hebron)
Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona

Data:	2021
Resum:	Metastatic small bowel low-grade neuroendocrine tumors (NETs) have a good prognosis. Surgery is the only curative treatment; however, this may induce advanced liver disease, particularly in long-term survivor patients. Acquired hepatocerebral degeneration or Parkinsonism in cirrhosis is characterized by rapidly progressive extrapyramidal symptoms in patients with advanced liver disease. A 70-year-old man presented to the emergency department with diminished consciousness and disorientation, and was diagnosed with hepatic encephalopathy. The patient was diagnosed in 1993 with a metastatic small bowel NET, for which he twice underwent hepatic surgery, with metastatic resection in 1993 and a right hepatectomy in 2002 to remove two hepatic metastases. In 2003, the patient started first-line chemotherapy and in 2004 started the first of three consecutive biological treatments, followed by radio-molecular therapy, achieving stable disease for 14 years. Disease progression was identified and he underwent an endoscopic retrograde cholangiopancreatography. However, in 2019 advanced liver disease was identified. We diagnosed the development of acquired hepatocerebral degeneration, an unusual long-term side effect after multiple hepatic procedures. The importance of regular and ongoing surveillance in long-term NET survivors who undergo hepatic procedures should be integrated into the therapeutic management plan, as some of these negative outcomes could be prevented.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Neuroendocrine tumors ; Hepatocerebral degeneration ; Parkinsonism ; Somatostatin analogues ; Everolimus ; Hepatic metastases ; Peptide radionuclide receptor therapy ; Encephalopathy ; Paramagnetic deposits ; Case report
Publicat a:	World Journal of Hepatology, Vol. 13 (may 2021) , p. 611-619, ISSN 1948-5182

DOI: 10.4254/wjh.v13.i5.611
PMID: 34131474

13 p, 11.2 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats